Hexvix (Hexaminolevulinate)

Hexvix is employed as a diagnostic adjunct during cystoscopic evaluation of the urinary bladder, where it helps identify lesions that may be missed under white‑light inspection.

• Detection of non‑muscle‑invasive bladder cancer (Ta, T1) during blue‑light cystoscopy.
• Visualization of carcinoma in situ (CIS) that is often flat and difficult to see.
• Enhancement of lesion identification after transurethral resection to assess completeness.
• Surveillance of patients with a history of bladder cancer for early recurrence.
• Adjunctive use in clinical studies evaluating new bladder‑cancer diagnostic protocols.

• Hexvix contains hexaminolevulinate, a prodrug that is preferentially taken up by malignant urothelial cells. Inside these cells, enzymatic conversion to protoporphyrin IX occurs, which accumulates because of altered heme biosynthesis. When the bladder is illuminated with blue light (≈400 nm), protoporphyrin IX fluoresces, producing a red‑pink glow that highlights cancerous tissue while normal urothelium remains non‑fluorescent. The selective accumulation provides contrast that assists the endoscopist in distinguishing malignant from benign areas.

Adverse reactions to Hexvix are generally related to the instillation procedure and the photosensitizing properties of the agent.

Common

• Mild bladder irritation or burning sensation during or shortly after instillation.
• Transient increase in urinary urgency, frequency, or mild dysuria.
• Temporary pinkish discoloration of urine that resolves spontaneously.
• Light‑induced discomfort of the bladder mucosa observed during blue‑light examination.
• Small amount of hematuria that clears within a few hours.

Serious

• Allergic reactions such as rash, pruritus, swelling, or angioedema requiring intervention.
• Severe cystitis or bladder inflammation presenting with pain, fever, or persistent hematuria.
• Photosensitivity reactions affecting adjacent pelvic tissues if excessive light exposure occurs.

When using Hexvix, clinicians should follow specific precautions to minimize risks and ensure accurate diagnostic results.

• Ensure the bladder is empty before instillation and maintain the recommended dwell time.
• Use sterile technique and avoid contamination of the solution.
• Verify that the patient has no known hypersensitivity to porphyrins or similar compounds.
• Monitor for urinary retention; do not exceed the recommended volume.
• Advise patients to avoid direct exposure of the treated bladder to intense light sources after the procedure.
• Document any adverse reactions and report serious events to regulatory authorities.
• Consider postponing the procedure in patients with active urinary tract infection.

Hexvix may interact with other agents or conditions that affect light exposure or porphyrin metabolism.

Avoid

• Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid) that could amplify fluorescence or cause systemic photosensitivity.
• Direct exposure of the bladder to intense external light sources during the dwell period.

Use with caution

• Patients receiving photodynamic therapy for other indications; monitor for cumulative photosensitivity.
• Use in individuals with severe hepatic impairment, as altered porphyrin clearance may increase tissue accumulation.
• Concomitant administration of drugs that affect heme synthesis (e.g., antiepileptics like phenobarbital) may modify fluorescence intensity.